Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of V160 in Healthy Japanese Men
NCT03840174Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2019
- Primary completion
- Nov 2019
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cytomegalovirus infection (CMV) comparing V160 with Placebo (2 arms). Primary endpoints: Percentage of Participants With a Solicited Injection-site Adverse Event, Percentage of Participants With a Solicited Systemic Adverse Event and 1 more. Started Mar 2019; status: completed.
02
Drugs
V160
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT03840174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03840174.